Atea Pharmaceuticals, Inc. financial data

Symbol
AVIR on Nasdaq
Industry
Pharmaceutical Preparations
Location
225 Franklin Street, Suite 2100, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.89K % -54.5%
Debt-to-equity 7.02 % +90.2%
Return On Equity -33.2 % -97.6%
Return On Assets -31.1 % -91.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.4M shares +1.23%
Common Stock, Shares, Outstanding 84.4M shares +1.23%
Entity Public Float 284M USD -47.2%
Common Stock, Value, Issued 84K USD +1.21%
Weighted Average Number of Shares Outstanding, Basic 84.3M shares +1.02%
Weighted Average Number of Shares Outstanding, Diluted 84.3M shares +1.02%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 155M USD +86.3%
General and Administrative Expense 48.6M USD -1.9%
Operating Income (Loss) -204M USD -53.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -175M USD -59.9%
Income Tax Expense (Benefit) 1.04M USD -3.19%
Net Income (Loss) Attributable to Parent -176M USD -65.8%
Earnings Per Share, Basic -2.09 USD/shares -64.6%
Earnings Per Share, Diluted -2.09 USD/shares -64.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 243M USD +13.9%
Cash, Cash Equivalents, and Short-term Investments 502M USD -17.4%
Accounts Receivable, after Allowance for Credit Loss, Current 4.51M USD
Assets, Current 506M USD -18.4%
Property, Plant and Equipment, Net 1.08M USD -27.8%
Operating Lease, Right-of-Use Asset 1.54M USD -27.1%
Other Assets, Noncurrent 1.4M USD 0%
Assets 510M USD -18.5%
Accounts Payable, Current 5.47M USD +38.1%
Employee-related Liabilities, Current 4.19M USD +11.2%
Liabilities, Current 26.6M USD +64.7%
Accrued Income Taxes, Noncurrent 6.05M USD +10.1%
Operating Lease, Liability, Noncurrent 1.25M USD -38.5%
Liabilities 33.9M USD +43.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -280K USD +9.68%
Retained Earnings (Accumulated Deficit) -300M USD -142%
Stockholders' Equity Attributable to Parent 476M USD -20.9%
Liabilities and Equity 510M USD -18.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.9M USD -33.6%
Net Cash Provided by (Used in) Financing Activities 150K USD -9.09%
Net Cash Provided by (Used in) Investing Activities -44K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 84.4M shares +1.23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 243M USD +13.8%
Deferred Tax Assets, Valuation Allowance 74.2M USD +80.2%
Deferred Tax Assets, Gross 74.2M USD +80.2%
Operating Lease, Liability 2.03M USD -26.8%
Payments to Acquire Property, Plant, and Equipment 44K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -176M USD -65.3%
Lessee, Operating Lease, Liability, to be Paid 2.1M USD -27.9%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 780K USD +5.41%
Lessee, Operating Lease, Liability, to be Paid, Year Two 855K USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 838K USD +2.07%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 79K USD -47.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 855K USD +2.03%
Deferred Tax Assets, Operating Loss Carryforwards 9.39M USD +67.9%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -3.83M USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 5.76M USD +9.57%
Lessee, Operating Lease, Liability, to be Paid, Year Four 855K USD +2.03%
Additional Paid in Capital 776M USD +6.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 49.8M USD +3.77%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%